Join us on summer camps for elderly people with diabetes!
Contact: Diabetes Association of Serbia, Karadjordjeva 36/II-5A, 11000 Belgrade, Serbia. Tel. + 381 11 3283267, 3283485
Fax. + 381 11 3283578
email: dorabeljic@beotel.net
Check out our “Guidelines for organizing camps for elderly people with diabetes”: http://www.diabeta.net/index.php?option=com_content&task=view&id=214&Itemid=121
Duration : 0:9:7
The American College of Physicians released a new clinical practice guideline on diagnosing and treating stable chronic obstructive pulmonary disease (COPD), a slowly progressive lung disease involving the airways and lung tissue, resulting in a gradual loss of lung function, typically as a result of smoking. COPD affects more than 5 percent of the adult population in the United States and is the fourth leading cause of death and twelfth leading cause of illness. The symptoms of COPD range from chronic cough and wheezing to more severe symptoms such as shortness of breath and significant activity limitation. The term COPD includes both emphysema and chronic bronchitis. Physicians often use the broader term COPD, since affected patients frequently have components of both conditions.
Duration : 0:2:23
http://pcp.onlinemindanao.com
Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries.
More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.
Duration : 0:7:21
From http://hhcbooks.com/respiratory_diseases/contemporary_diagnosis_and_management_of_copd – Leading Pulmonology experts Antonio Anzueto and Fernando Martinez talk about what’s new in the field of COPD
Duration : 0:7:33
New information and treatment considerations for Asthma.
Duration : 0:52:26
http://www.pcp.onlinemindanao.com
http://www.PhilippinesDailyPhotos.com
http://www.JourneyPhilippines.net
http://www.CagayandeOroBlog.com
Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries.
More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.
Duration : 0:6:45
http://pcp.onlinemindanao.com
Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries.
More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.
Duration : 0:7:11
Mayo Clinic endocrinologist Victor Montori, M.D., describes his analysis of several large randomized trials involving patients with type 2 diabetes, and the implications for treatment guidelines. http://newsblog.mayoclinic.org/2009/04/18/type-2-diabetes-management-mayo-clinic/
Duration : 0:9:36
One-third of diabetics don’t know that they have the condition. How can you avoid being one of them? Check out this video!Watch More Health Videos at Health Guru: http://www.healthguru.com/?YT
Duration : 0:2:55
